Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 2NIH 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Neoplasms 2Ovarian Neoplasms 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Brain Neoplasms 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 297Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × cositecan × Clear all
NCT00062478 2020-03-12

Study of Karenitecin (BNP1350) in Patients With Brain Tumors

BioNumerik Pharmaceuticals, Inc.

Phase 2 Completed
40 enrolled
CNS

Brain Neoplasms

NCT00062491 2020-03-12

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

BioNumerik Pharmaceuticals, Inc.

Phase 2 Completed
46 enrolled
Dermatologic

Melanoma, Neoplasms

NCT00097903 2020-03-12

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

BioNumerik Pharmaceuticals, Inc.

Phase 1 Completed
32 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT00477282 2020-03-12

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
509 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡